LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Marina Biotech is a clinical stage biotechnology company focused on development and commercialization of therapeutic products for rare diseases based on RNA interference (RNAi). The company is developing proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds intended to trigger various RNA-based mechanisms of action including RNA interference, microRNA replacement therapy, microRNA inhibition and mRNA translational inhibition, respectively.
Marina Biotech
Bothell, WA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.